Resveratrol-loaded invasome gel: A promising nanoformulation for treatment of skin cancer
Drug Delivery and Translational Research · 2024
DOI: 10.1007/s13346-024-01534-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2024. Verfasst von Bassant Samir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, 1 Khartoum Square, Azarita, P.O. Box 21521, Alexandria, Egypt. Hauptthemen laut MEDLINE: Resveratrol, Skin Neoplasms, Gels. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexandria University.
Abstract (Originalsprache)
Skin cancer is a widespread type of cancer representing 30% of all cancer types worldwide. Resveratrol (RSV) is an anticancer drug used for skin cancer treatment. Several limitations of RSV such as poor aqueous solubility, first-pass metabolism, and instability limit their topical use. The study aimed to develop and optimize RSV-loaded invasomes for topical administration as well as assess their efficacy in vivo. The optimized RSV-loaded invasomes showed small particle size (208.7 ± 74 nm), PDI (0.3 ± 0.03), high % entrapment efficiency (77.7 ± 6%), and negative zeta potential (−70.4 ± 10.9 mV). They showed an initial burst effect followed by controlled drug release for 24 h. RSV-loaded invasomal gel revealed the highest skin deposition percentage (65%) in ex vivo rat skin, the highest potency (low IC 50 of 6.34 μg/mL), and the highest cellular uptake when tested on squamous cancerous cells (SCCs) when compared to other formulations. The antitumor effect of topical RSV-loaded invasomes was also evaluated in vivo in Ehrlich-induced mice models. The results revealed that RSV-loaded invasomal gel exhibited the smallest tumor volume with no signs of organ toxicity indicating its safety in skin cancer treatment. Upregulation of BAX and Caspase-3 gene levels and downregulation of NF-kB and BCL2 protein levels were demonstrated using RT-PCR and ELISA tests, respectively. Interestingly, the present study is the first to develop RSV-loaded invasomal gel for topical skin cancer treatment. According to our results, invasomes are considered promising lipid-based nanosystems for topical RSV delivery having high skin penetration ability and anticancer effect in the treatment of skin carcinoma. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, 1 Khartoum Square, Azarita, P.O. Box 21521, Alexandria, Egypt.
- Department of Histology and Cell Biology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, 1 Khartoum Square, Azarita, P.O. Box 21521, Alexandria, Egypt. lamia.heikal@alexu.edu.eg.
ORCID-Profile: Amal El-Kamel, Noha Zahran, Lamia Heikal
Förderung
- Alexandria University
Zitieren
APA
Samir, B., El-Kamel, A., Zahran, N., & Heikal, L. (2024). Resveratrol-loaded invasome gel: A promising nanoformulation for treatment of skin cancer. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01534-9
Vancouver
Samir B, El-Kamel A, Zahran N, Heikal L. Resveratrol-loaded invasome gel: A promising nanoformulation for treatment of skin cancer. Drug Delivery and Translational Research. 2024. doi:10.1007/s13346-024-01534-9
BibTeX
@article{Samir2024,
author = {Samir, Bassant and El-Kamel, Amal and Zahran, Noha and Heikal, Lamia},
title = {Resveratrol-loaded invasome gel: A promising nanoformulation for treatment of skin cancer},
journal = {Drug Delivery and Translational Research},
year = {2024},
doi = {10.1007/s13346-024-01534-9}
}
EUVIMED